[go: up one dir, main page]

MX2020009745A - Composiciones farmaceuticas que comprenden fumarato de dimetilo. - Google Patents

Composiciones farmaceuticas que comprenden fumarato de dimetilo.

Info

Publication number
MX2020009745A
MX2020009745A MX2020009745A MX2020009745A MX2020009745A MX 2020009745 A MX2020009745 A MX 2020009745A MX 2020009745 A MX2020009745 A MX 2020009745A MX 2020009745 A MX2020009745 A MX 2020009745A MX 2020009745 A MX2020009745 A MX 2020009745A
Authority
MX
Mexico
Prior art keywords
dimethyl fumarate
pharmaceutical compositions
starch
compositions
gastro
Prior art date
Application number
MX2020009745A
Other languages
English (en)
Inventor
JIMENEZ María PLANELLS
Lopez Begoña Duarte
Coll Pere Guiro
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020009745(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2020009745A publication Critical patent/MX2020009745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen composiciones farmacéuticas que comprenden (a) fumarato de dimetilo, (b) un diluyente seleccionado de monosacáridos, disacáridos, almidón y derivados de almidón, sales inorgánicas de calcio y magnesio, alcoholes de azúcares, y mezclas de ellos, (c) celulosa microcristalina y (d) croscarmelosa sódica, donde el fumarato de dimetilo no está recubierto con una cubierta gastrorresistente. Estas composiciones están destinadas al tratamiento de algunas enfermedades inflamatorias o trastornos autoinmunes.
MX2020009745A 2013-12-12 2016-06-01 Composiciones farmaceuticas que comprenden fumarato de dimetilo. MX2020009745A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382504 2013-12-12

Publications (1)

Publication Number Publication Date
MX2020009745A true MX2020009745A (es) 2020-10-08

Family

ID=49917530

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016007105A MX375144B (es) 2013-12-12 2014-12-05 Composiciones farmacéuticas que comprenden fumarato de dimetilo.
MX2020009745A MX2020009745A (es) 2013-12-12 2016-06-01 Composiciones farmaceuticas que comprenden fumarato de dimetilo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016007105A MX375144B (es) 2013-12-12 2014-12-05 Composiciones farmacéuticas que comprenden fumarato de dimetilo.

Country Status (31)

Country Link
US (2) US20160310457A1 (es)
EP (2) EP3656379A1 (es)
JP (3) JP6581088B2 (es)
KR (2) KR102353201B1 (es)
CN (2) CN105813634A (es)
AR (1) AR098746A1 (es)
AU (2) AU2014363792B2 (es)
BR (1) BR112016012179B1 (es)
CA (2) CA3135273A1 (es)
CL (1) CL2016001415A1 (es)
CY (1) CY1124336T1 (es)
DK (1) DK3079666T3 (es)
EA (1) EA201600457A1 (es)
ES (1) ES2860551T3 (es)
HR (1) HRP20210468T1 (es)
HU (1) HUE054408T2 (es)
IL (2) IL287109B (es)
LT (1) LT3079666T (es)
MX (2) MX375144B (es)
MY (1) MY179355A (es)
NZ (2) NZ720287A (es)
PH (2) PH12016501043A1 (es)
PL (1) PL3079666T3 (es)
PT (1) PT3079666T (es)
RS (1) RS61658B1 (es)
SG (3) SG10201802815UA (es)
SI (1) SI3079666T1 (es)
SM (1) SMT202100205T1 (es)
TW (2) TWI687218B (es)
UA (2) UA120428C2 (es)
WO (1) WO2015086467A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10085961B2 (en) 2015-06-01 2018-10-02 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
WO2016205754A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2017040272A1 (en) * 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
EA201800403A1 (ru) 2015-12-31 2018-12-28 Заклады Фармацеутицне Польфарма С.А. Способ получения покрытого кишечнорастворимой оболочкой гранулята, содержащего диметилфумарат
PL3407873T3 (pl) * 2016-01-28 2025-01-13 Zakłady Farmaceutyczne POLPHARMA S.A. Sposób otrzymywania granulatu zawierającego fumaran dimetylu
AU2017216861A1 (en) * 2016-02-12 2018-10-04 Universität Zürich Dimethyl fumarate (DMF) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
CN110636838A (zh) * 2017-06-23 2019-12-31 阿尔米雷尔有限公司 包含反丁烯二酸二甲酯的药物组合物
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
WO2020053218A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
WO2020053219A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
MX2021012441A (es) * 2019-05-31 2022-10-07 Curacle Co Ltd Tableta enterica que contiene fumarato de dimetilo.
CN112996850B (zh) * 2019-11-07 2022-06-03 旭化成株式会社 纤维素组合物及片剂
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
KR20220133807A (ko) * 2021-03-25 2022-10-05 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
EP4313023A1 (en) * 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
US20240374632A1 (en) * 2023-05-11 2024-11-14 Yon Doo Ough Apparatus and Method for Contact Free Delivery and Administration of Magnesium as a Drug

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
ES2582942T3 (es) * 2004-10-08 2016-09-16 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
SI1877059T1 (sl) * 2005-04-28 2010-07-30 Wyeth Llc Mikroniziran tanaproget in sestavki, ki ga vsebujejo
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
CN101304732A (zh) * 2005-10-07 2008-11-12 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
EP2379063B2 (en) 2009-01-09 2021-02-24 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
CN102369000A (zh) 2009-01-09 2012-03-07 前进制药公司 包含一种或多种富马酸酯的药用组合物
US20120165404A1 (en) * 2009-04-29 2012-06-28 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation
CN103582479A (zh) * 2011-06-03 2014-02-12 霍夫曼-拉罗奇有限公司 用pi3k抑制剂化合物治疗间皮瘤的方法
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
KR102105217B1 (ko) 2012-02-07 2020-06-01 바이오젠 엠에이 인코포레이티드 다이메틸 푸마레이트를 함유하는 약학 조성물

Also Published As

Publication number Publication date
RS61658B1 (sr) 2021-04-29
SG10201913080VA (en) 2020-03-30
AU2014363792B2 (en) 2019-11-14
ES2860551T3 (es) 2021-10-05
CY1124336T1 (el) 2022-07-22
TWI687218B (zh) 2020-03-11
HK1224212A1 (en) 2017-08-18
KR20210150587A (ko) 2021-12-10
SMT202100205T1 (it) 2021-07-12
IL287109A (en) 2021-12-01
IL245685A0 (en) 2016-06-30
CA3135273A1 (en) 2015-06-18
UA123880C2 (uk) 2021-06-16
JP6945603B2 (ja) 2021-10-06
MX2016007105A (es) 2016-08-11
JP2016540003A (ja) 2016-12-22
US20160310457A1 (en) 2016-10-27
TWI704915B (zh) 2020-09-21
CL2016001415A1 (es) 2017-01-20
LT3079666T (lt) 2021-03-25
PL3079666T3 (pl) 2021-09-06
PH12016501043B1 (en) 2016-07-04
CN114159421B (zh) 2023-08-25
AR098746A1 (es) 2016-06-08
WO2015086467A1 (en) 2015-06-18
PH12019502610A1 (en) 2021-02-22
TW201605435A (zh) 2016-02-16
EA201600457A1 (ru) 2016-11-30
SG10201913076PA (en) 2020-02-27
CA2932054C (en) 2022-09-20
BR112016012179A2 (es) 2017-08-08
AU2019268075A1 (en) 2019-12-12
HRP20210468T1 (hr) 2021-05-14
UA120428C2 (uk) 2019-12-10
SI3079666T1 (sl) 2021-04-30
HUE054408T2 (hu) 2021-09-28
AU2019268075B2 (en) 2020-12-17
JP2021130689A (ja) 2021-09-09
PH12016501043A1 (en) 2016-07-04
DK3079666T3 (da) 2021-03-22
BR112016012179B1 (pt) 2023-04-18
KR102335289B1 (ko) 2021-12-06
CN114159421A (zh) 2022-03-11
NZ759411A (en) 2020-06-26
JP2019218385A (ja) 2019-12-26
IL245685B (en) 2021-10-31
US20210330628A1 (en) 2021-10-28
KR20160089397A (ko) 2016-07-27
EP3079666A1 (en) 2016-10-19
JP6581088B2 (ja) 2019-09-25
KR102353201B1 (ko) 2022-01-18
PT3079666T (pt) 2021-02-18
MX375144B (es) 2025-03-06
CN105813634A (zh) 2016-07-27
MY179355A (en) 2020-11-05
CA2932054A1 (en) 2015-06-18
TW202011953A (zh) 2020-04-01
NZ720287A (en) 2020-05-29
EP3079666B1 (en) 2021-02-03
SG10201802815UA (en) 2018-05-30
AU2014363792A1 (en) 2016-06-09
EP3656379A1 (en) 2020-05-27
IL287109B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
PH12019502610A1 (en) Pharmaceutical compositions comprising dimenthyl fumarate
HUE054389T2 (hu) Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
GB2547397A (en) Configuration based cache coherency protocol selection
EP4349406A3 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament
EA201790785A1 (ru) Производные тетрагидроизохинолина
SMT202100082T1 (it) Composti eteroarilici per il trattamento di malattie oftalmiche
EP3406184A4 (en) PROCESSOR FOR ENDOSCOPE
WO2017008033A8 (en) Pyrrolidine carboxamido derivatives and methods for preparing and using the same
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
EP3143800A4 (en) Reduced handover latency for licensed shared access
EP3096775A4 (en) Socs mimetics for the treatment of diseases
EP3593265B8 (en) Controlling user access to a medical system
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
IL259381B (en) Mirabegron for the treatment of retinal diseases
EP3024326A4 (en) Novel process for the preparation of levothyroxine sodium
PH12015502703A1 (en) Pharmaceutical compositions
IL256812A (en) Heteroaryl carbonitriles for the treatment of disease
EP3189847A4 (en) Therapeutic or prophylactic agent for itching skin diseases
AU2018904527A0 (en) Low latency inter-processor signalling
HK1216150A1 (zh) 匹多莫德治疗炎症性肠病的用途
HK40006674A (zh) 用於治疗疾病之神经醯胺半乳糖基转移酶抑制剂
AU2015905202A0 (en) Orthopaedic Bunion Splint
UA91650U (uk) Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул
PH12015502304A1 (en) Use of pidotimod to treat irritable bowel syndrome